Literature DB >> 28948162

Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat?

Gabriele Biondi1, Giovanni Sotgiu2, Simone Dore2, Paola Molicotti3, Melania Ruggeri3, Stefano Aliberti4,5, Rosanna Satta1.   

Abstract

Pulmonary and extra-pulmonary diseases caused by nontuberculous mycobacteria: new clinical and public health threats http://ow.ly/87Dm30eMFd9.

Entities:  

Year:  2017        PMID: 28948162      PMCID: PMC5603771          DOI: 10.1183/23120541.00091-2017

Source DB:  PubMed          Journal:  ERJ Open Res        ISSN: 2312-0541


To the Editor: Nontuberculous mycobacteria (NTM) are a heterogeneous group of pathogens including all mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae [1]. The rate of NTM infection has increased substantially over the last decades, especially in high-income countries, as recently illustrated by Diel et al. [2] who have highlighted the relevant clinical and economic burden of NTM disease in Germany. The main reasons include the aging of the population, the increasing number of patients with immunodepressive disorders, the use of immunosuppressive agents and a substantial increase in awareness of the disease [3]. Epidemiological data on NTM worldwide are lacking and very few reports have been published based on the Italian population [4, 5]. An assessment of the temporal trends of positive cultures for NTM on one of the two major islands of Italy, Sardinia, has been performed recently in the microbiology laboratory of the University of Sassari, through the collection of data on both M. tuberculosis and NTM from January 01 2012 to December 31 2015. Among the 212 positive samples identified during the study period, 162 (76.4%) were positive for M. tuberculosis and 50 (23.6%) for NTM. Positive samples were obtained from 126 males (NTM: 27, 21.4%; M. tuberculosis: 99, 78.6%) and 83 females (NTM: 23, 27.7%; M. tuberculosis: 60, 72.3%) with three subjects being of unknown gender. Patients' median age was 49 years (IQR: 35–71) for the entire cohort, 61 years (IQR: 38–78) for the NTM group and 46 years (IQR: 35–66) for the M. tuberculosis group. The lung was the most frequently affected organ for both M. tuberculosis (124, 76.5%) and NTM (32, 64.0%). Furthermore, M. tuberculosis was also isolated from stomach (15, 9.3%), lymph node (6, 3.7%), skin (5, 3.1%) and urogenital tract (5, 3.1%) samples while NTM were also found in skin (8, 16.0%) and lymph node (7, 14.0%) samples (table 1). The most commonly isolated NTM species was Mycobacterium avium (16, 32.0%), followed by Mycobacterium xenopi (9, 18.0%), Mycobacterium gordonae (8, 16.0%) and Mycobacterium chelonae (6, 12.0%). The NTM species isolated from the lung included M. avium (10, 31.3%), M. xenopi (8, 25.0%) and M. gordonae (7, 21.9%), while the NTM isolated from cutaneous samples were M. chelonae (5, 62.5%) and Mycobacterium marinum (3, 37.5%). Of these last two NTM species, the former was isolated from cutaneous samples in 83.3% of cases, while the latter was isolated only from skin.
TABLE 1

Prevalence of nontuberculous mycobacteria (NTM) in an Italian cohort, 2012–2015

LungStomachSkinBone marrowLymph nodesTotal
M. avium10 (62.5, 38.8–86.2)1 (6.3, −5.6–82.7)5 (31.3, 8.6–54.0)16/50 (32.0, 19.1–44.9)
M. gordonae7 (87.5, 71.3–100.0)1 (12.5, −10.4–35.4)8/50 (16.0, 5.8–26.2)
M. chelonae1 (16.7, −13.1–46.5)5 (83.3, 53.5–100.0)6/50 (12.0, 3.0–21.0)
M. xenopi8 (88.9, 68.4–100.0)1 (11.1, −9.4–31.6)9/50 (18.0, 7.4–28.7)
M. abscessus2 (100.0, 100.0–100.0)2/50 (4.0, −1.4–9.4)
M. intracellulare1 (100.0, 100.0–100.0)1/50 (2.0, −1.9–5.9)
M. scrofulaceum2 (100.0, 100.0–100.0)2/50 (4.0, −1.4–9.4)
M. fortuitum1 (100.0, 100.0–100.0)1/50 (2.0, −1.9–5.9)
M. marinum3 (100.0, 100.0–100.0)3/50 (6.0, −0.6–12.6)
M. szulgai1 (100.0, 100.0–100.0)1/50 (2.0, −1.9–5.9)
M. simiae1 (100.0, 100.0–100.0)1/50 (2.0, −1.9–5.9)
Total32 (64.0, 50.7–77.3)2 (4.0, −1.4–9.4)8 (16.0, 5.8–26.2)1 (2.0, −1.9–5.9)7 (14.0, 4.4–23.6)

Data are presented as n (%, 95% CI) unless otherwise stated.

Prevalence of nontuberculous mycobacteria (NTM) in an Italian cohort, 2012–2015 Data are presented as n (%, 95% CI) unless otherwise stated. Patients with NTM infection were statistically older than patients with M. tuberculosis infection (p-value: 0.04) and this finding underlines the importance of age-related immunosurveillance in keeping NTM infections under control. The elderly are more susceptible to developing NTM infection due to immunosenescence, a higher prevalence of immunodepressive diseases and a wider use of immunosuppressive drugs. The skin and the lymph nodes were more often associated with NTM infection (8, 16.0% and 7, 14.0%; p-value: 0.003) compared to infection by M. tuberculosis (5, 3.1% and 6, 3.7%; p-value: 0.02), highlighting how NTM are gaining importance in non-pulmonary infections. Among the NTM species isolated from cutaneous samples, M. chelonae was more prevalent and overcame M. marinum, affirming its role as an emerging pathogen in cutaneous infections. NTM infection involved the skin in 16% of cases, as has been reported previously [3, 6, 7]; however, this prevalence is higher than in previous national [5] and local [8] data, demonstrating an increasing diagnostic sensitivity and interest in this topic. Different points may be drawn from these findings as highlights, namely: 1) M. chelonae is emerging as a cutaneous pathogen; 2) Mycobacterial cutaneous infections are nowadays more commonly due to NTM than M. tuberculosis; 3) A multidisciplinary approach, higher diagnostic accuracy in the laboratory setting and increasing awareness in the notification of the public health authorities are needed. Finally, NTM-derived lung disease remains an important field for future clinical research and patients' initiatives and international registries, such as the Bronchiectasis and NTM Research Registry in the United States or the Italian REgistry of pulmonary Non-tuberculous mycobactEria (IRENE) [9, 10], might play a crucial role in improving our knowledge of the epidemiologic situation, which will in turn help create control programmes for these patients.
  9 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Identification of non-tuberculous mycobacteria from clinical samples.

Authors:  Paola Molicotti; Alessandra Bua; Sara Cannas; Maria Cubeddu; Melania Ruggeri; Piero Pirina; Stefania Zanetti
Journal:  New Microbiol       Date:  2013-10-01       Impact factor: 2.479

3.  Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Authors:  Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop
Journal:  Chest       Date:  2017-05-05       Impact factor: 9.410

4.  Burden of non-tuberculous mycobacterial pulmonary disease in Germany.

Authors:  Roland Diel; Josephine Jacob; Niklas Lampenius; Michael Loebinger; Albert Nienhaus; Klaus F Rabe; Felix C Ringshausen
Journal:  Eur Respir J       Date:  2017-04-26       Impact factor: 16.671

5.  Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006-2010.

Authors:  Genee S Smith; Andrew J Ghio; Jason E Stout; Kyle P Messier; Edward E Hudgens; Mark S Murphy; Stacy L Pfaller; Jean-Marie Maillard; Elizabeth D Hilborn
Journal:  J Infect       Date:  2016-03-18       Impact factor: 6.072

6.  Epidemiology of Rapidly Growing Mycobacteria Bloodstream Infections.

Authors:  Michelle A Rodriguez-Coste; Ioana Chirca; Lisa L Steed; Cassandra D Salgado
Journal:  Am J Med Sci       Date:  2016-03       Impact factor: 2.378

7.  Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects.

Authors:  Mehdi Mirsaeidi; Parissa Farnia; Ruxana Sadikot; Po-Ren Hsueh; Stefano Aliberti
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

8.  Inventory study of non-tuberculous mycobacteria in the European Union.

Authors:  Marieke J van der Werf; Csaba Ködmön; Vera Katalinić-Janković; Tiina Kummik; Hanna Soini; Elvira Richter; Dimitrios Papaventsis; Enrico Tortoli; Monique Perrin; Dick van Soolingen; Manca Zolnir-Dovč; Vibeke Ostergaard Thomsen
Journal:  BMC Infect Dis       Date:  2014-02-06       Impact factor: 3.090

9.  Increase in non-tuberculous mycobacteria isolated from humans in Tuscany, Italy, from 2004 to 2014.

Authors:  Laura Rindi; Carlo Garzelli
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

  9 in total
  2 in total

1.  The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Authors:  Stefano Aliberti; Luigi Ruffo Codecasa; Andrea Gori; Giovanni Sotgiu; Maura Spotti; Antonio Di Biagio; Andrea Calcagno; Stefano Nardini; Baroukh Maurice Assael; Enrico Tortoli; Giorgio Besozzi; Maurizio Ferrarese; Alberto Matteelli; Enrico Girardi; Saverio De Lorenzo; Manuela Seia; Andrea Gramegna; Bruno Del Prato; Leonardo Terranova; Martina Oriano; Nicola Sverzellati; Mehdi Mirsaeidi; James D Chalmers; Charles S Haworth; Michael R Loebinger; Timothy Aksamit; Kevin Winthrop; Felix C Ringshausen; Giuliana Previdi; Francesco Blasi
Journal:  Multidiscip Respir Med       Date:  2018-08-09

2.  Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection.

Authors:  Timothy David Shaw; Mark Smyth; Graham Turner; Michael Hunter
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-07-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.